In the competitive multiple sclerosis treatment market, understanding the 'why' behind prescribing decisions makes the difference between market leadership and missed opportunity. This report offers unprecedented visibility into the minds of neurologists and MS specialists to reveal core psychological drivers that influence disease modifying treatment (DMT) selection and shape real-world prescription behaviour.
Ipsos' Brand Value Creator (BVC) measures the desire to use a particular therapy (attitudinal equity) against constraints preventing its usage (barrier effects) and quantifies their relative impact on market share. This robust and time-tested methodology - based on insights from approximately 235 healthcare professionals across the EU4 and UK - will allow you to understand how HCPs make choices and how to grow your brand.
Through comprehensive questioning about treatment preferences, perceptions, and prescribing patterns, we transform complex decision-making processes into clear, actionable intelligence for pharmaceutical and biotech stakeholders looking to optimise their MS brand market strategy.
- Access detailed prescribing data across MS subtypes to map market dynamics and pinpoint your competitive position
- Measure your brand's psychological strength and attitudinal equity against key competitors in the minds of prescribers
- Identify gaps between physician preference and product performance to create highly targeted and effective messaging
- Discover which product attributes truly influence treatment selection, revealing both conscious and unconscious decision drivers
- Visualise your brand's perceived strengths and weaknesses against competitors to defend share and identify opportunities
- Insights from a robust data source based on long-established methodology
- Physician-stated and real-world patient findings blended for a holistic view
- Curated by Ipsos' dedicated neurology experts
Sample excerpt from report
- 20 slides
- Data collection timeframe: Q2 2025
- Data source: Ipsos Multiple Sclerosis Therapy Monitor
- Respondent type: HCPs
- Regions shown: Aggregate of France, Germany, Italy, Spain, UK
- Consistent global data, large-scale datasets